Compare GSK plc (GSK) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Zillow Group Inc Class A — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: GSK plc is far larger — about 13.9× Zillow Group Inc Class A's market cap, and GSK plc pays a 3.9% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Zillow Group Inc Class A for 86 Days on average.
| GSK | ZG | |
|---|---|---|
Market Cap | $91.88B | $6.59B |
Volume | 7,730,529 | 1,361,381 |
Sector | Health | Media |
52-Week High | $61.18 | $74.58 |
52-Week Low | $43.24 | $27.70 |
Typical Hold Time | 93 Days | 86 Days |
Enterprise Value | $111.88B | $6.47B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Zillow Group (ZG) trades at $29.87, up 6.79% on the day, showing strong momentum despite mixed technical signals. The company has demonstrated improved financial performance with revenue growth from $2.2B in 2024 to $2.6B in 2025 and achieving profitability with $23M net income after three years of losses. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though Q4 2025 missed expectations. Analyst consensus remains divided with a Hold rating but offers significant upside potential with a $48.87 price target.
The outlook for ZG appears cautiously optimistic with fundamental improvement offset by housing market headwinds. Investment opportunity lies in the company's transition to profitability and market share gains in digital real estate, while risks include interest rate sensitivity, competitive pressures from Compass, and ongoing housing affordability challenges that could impact transaction volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
